About this book:

*Hospira Inc.: The Story of An American Company* charts the remarkable journey of Hospira, a global leader in generic injectable pharmaceuticals and infusion technologies, from its roots as a division of Abbott Laboratories to its eventual acquisition by Pfizer. This comprehensive narrative delves into Hospira's origins, detailing how decades of innovation within Abbott's hospital products division laid the groundwork for its spin-off in 2004. The book explores Hospira's early years as an independent S&P 500 company, highlighting its rapid ascent to market dominance through strategic focus on cost-effective injectable medications, integrated infusion therapy, and its robust "One 2 One" contract manufacturing business. It also covers the meticulous process of building the Hospira brand, reflecting its mission of patient care and hope.

The book intricately details Hospira's expansive growth strategy, including pivotal acquisitions like Mayne Pharma, which doubled its international sales and bolstered its oncology portfolio, and Orchid Chemicals & Pharmaceuticals, which strengthened its position in antibiotics and established a key manufacturing footprint in India. It examines the company's foresight in venturing into healthcare informatics with the acquisition of TheraDoc and its innovation in pain management through Javelin Pharmaceuticals. However, the narrative doesn't shy away from the significant challenges Hospira faced, particularly the persistent manufacturing quality control issues and regulatory battles with the FDA, especially at its flagship Rocky Mount facility, which led to numerous product recalls and restructuring efforts like Project Fuel. The book culminates with the detailed account of Pfizer's strategic interest and the $17 billion acquisition in 2015, analyzing the transition and transformation of Hospira's assets and legacy within the larger pharmaceutical giant. This story offers invaluable insights into the complexities of global pharmaceutical manufacturing, market leadership, and the critical balance between efficiency, innovation, and patient safety.

What You'll Find Inside:

• **Pioneering Generic Injectables:** Learn how Hospira became the world's leading provider of generic injectable pharmaceuticals, significantly contributing to affordable healthcare and access to critical medicines.
• **Innovations in Infusion Therapy:** Discover Hospira's advancements in integrated infusion therapy and medication management systems, including smart pumps and safety software that enhanced patient safety and clinical efficiency.
• **Strategic Acquisitions & Global Growth:** Explore key acquisitions like Mayne Pharma and Orchid Chemicals & Pharmaceuticals that dramatically expanded Hospira's international footprint, product portfolio, and manufacturing capabilities, especially in oncology and antibiotics.
• **Navigating Regulatory Challenges:** Understand the persistent manufacturing quality issues and subsequent legal battles with the FDA, particularly at the Rocky Mount facility, and the company's extensive efforts to address them.
• **Pivotal Role in Biosimilars:** Trace Hospira's early entry and leadership in the burgeoning biosimilars market, offering cost-effective alternatives to complex biological drugs and influencing Pfizer's strategy in this high-growth area.

Who's It For:

This book is essential reading for professionals and students in the pharmaceutical and medical device industries, including those in manufacturing, quality control, regulatory affairs, and supply chain management. It also provides valuable insights for healthcare administrators, investors, and business historians interested in the complexities of corporate spin-offs, strategic acquisitions, and the challenges of maintaining quality and compliance in a highly regulated global industry.